Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs

J Robertson; D Lang; S Hill

doi:10.1046/j.1365-2710.2003.00452.x

Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs

J Clin Pharm Ther. 2003 Feb;28(1):73-9. doi: 10.1046/j.1365-2710.2003.00452.x.

Authors

J Robertson¹, D Lang, S Hill

Affiliation

¹ Clinical Pharmacology, School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, NSW Australia. jroberts@mail.newcastle.edu.au

PMID: 12605622
DOI: 10.1046/j.1365-2710.2003.00452.x

Abstract

This paper addresses pharmacoeconomics in prescribing research and reflects the increasing use of techniques of economic evaluation to aid drug purchasing decisions in a variety of settings -- for national drug subsidization programmes, provincial purchasing plans, insurance programmes, and for hospital and area health authority formulary decisions. First, we focus on the cost component of an economic evaluation and discuss methodological issues that are relevant to all pharmacoeconomic analyses.

MeSH terms

Cost Control
Cost-Benefit Analysis
Drug Costs
Drug Prescriptions
Drug Utilization Review / methods*
Economics, Pharmaceutical*
Humans
Pharmaceutical Preparations / economics*
Research Design*

Substances

Pharmaceutical Preparations